Showing 1291-1300 of 5062 results for "".
Systemic Treatment for Skin Cancers
https://practicaldermatology.com/topics/skin-cancer-photoprotection/systemic-treatment-for-skin-cancers/19662/Anisha B. Patel, MD discusses the latest advances in systemic treatment for melanoma with host Joshua Zeichner, MD. She reviews how treatments work, the most common cutaneous reactions patients experience, and the dermatologist's role in managing those reactions and reassuring patients that these rePhysician Spotlight With A. Yasmine Kirkorian, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-with-a-yasmine-kirkorian-md/23082/A Closer Look at Skyrizi
https://practicaldermatology.com/columns/clinical-focus-1/a-closer-look-at-skyrizi/23016/The newest IL-23 blocker for psoriasis may prove to be a blockbuster, according to analysts.Harnessing the Power of Humor for Psoriasis
https://practicaldermatology.com/topics/psoriasis/harnessing-the-power-of-humor-for-psoriasis/23007/Humor can create positive changes in our thoughts, feelings, behaviors, and biochemistry and can also influence how patients cope.Altreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for DuobA Review of Incident to Services
https://practicaldermatology.com/topics/practice-management/a-review-of-incident-to-services/20526/In order to ensure correct billing—and reimbursements—it is important to understand incident to policies.Content Marketing for Dermatologists
https://practicaldermatology.com/topics/practice-management/content-marketing-for-dermatologists/20536/A mix of time-sensitive and evergreen content is best to optimize engagement.Allergan's Cool Campaign, Obagi Line Launches, Apple Upgrades Health App
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-s-cool-campaign-obagi-line-launches-apple-upgrades-health-app/18346/There's some misleading information about fat reduction out there, and that's not cool, Allergan says. The company's CoolSculpting device has launched the “Not Cool Vs. Cool” campaign. Data show patients and doctors assess scars differently: Patients tend to focus on scar depth, while physicians focTwo Launches from Cutera, AmSpa Projections
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-two-launches-from-cutera-amspa-projections/18356/Cutera introduces two new devices to its laser and energy-based device offerings: Juliet laser represents Cutera's first entry into the women's health segment of the aesthetics market; Secret RF is a new fractional radio frequency microneedling device that effectively remodels collagen, improves milJanssen Approvals, New Thermage FLX, Restylane Silk Cannulas
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-janssen-approvals-new-thermage-flx-restylane-silk-cannulas/18401/Janssen Biotech's Stelara is now approved for the treatment of adolescents 12 years of age or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Janssen's SIMPONI ARIA® cleared for the treatment of adults with active psoriatic arthritis or active